[go: up one dir, main page]

EP1268526A4 - Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique - Google Patents

Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique

Info

Publication number
EP1268526A4
EP1268526A4 EP01922630A EP01922630A EP1268526A4 EP 1268526 A4 EP1268526 A4 EP 1268526A4 EP 01922630 A EP01922630 A EP 01922630A EP 01922630 A EP01922630 A EP 01922630A EP 1268526 A4 EP1268526 A4 EP 1268526A4
Authority
EP
European Patent Office
Prior art keywords
specific
testis
polypeptides
diagnostic
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01922630A
Other languages
German (de)
English (en)
Other versions
EP1268526A2 (fr
Inventor
Fahri Saatcioglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1268526A2 publication Critical patent/EP1268526A2/fr
Publication of EP1268526A4 publication Critical patent/EP1268526A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP01922630A 2000-03-24 2001-03-23 Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique Withdrawn EP1268526A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19192900P 2000-03-24 2000-03-24
US191929P 2000-03-24
PCT/US2001/009410 WO2001072962A2 (fr) 2000-03-24 2001-03-23 Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique

Publications (2)

Publication Number Publication Date
EP1268526A2 EP1268526A2 (fr) 2003-01-02
EP1268526A4 true EP1268526A4 (fr) 2004-09-08

Family

ID=22707491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01922630A Withdrawn EP1268526A4 (fr) 2000-03-24 2001-03-23 Molecules d'acide nucleique specifiques de la prostate ou des testicules, polypeptides, techniques de diagnostic, et traitement therapeutique

Country Status (5)

Country Link
EP (1) EP1268526A4 (fr)
JP (1) JP2004521602A (fr)
AU (2) AU2001249411B2 (fr)
CA (1) CA2403637A1 (fr)
WO (1) WO2001072962A2 (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1086223T3 (da) 1998-06-01 2009-11-30 Agensys Inc Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20040048798A1 (en) * 1999-06-01 2004-03-11 Raitano Arthur B. Nucleic acid and corresponding protein entitle 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EP1328151A4 (fr) * 1999-04-29 2004-06-16 Univ Tennessee Res Corp Acides nucleiques isoles de la famille p-hyde, proteines p-hyde et procede pour induire la susceptibilite a l'induction de la mort cellulaire programmee pendant le cancer
US6835812B1 (en) 1999-04-29 2004-12-28 University Of Tennessee Research Corporation Human p-Hyde proteins
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2005114216A2 (fr) * 2005-02-22 2005-12-01 Biomedisinsk Innovasjon As Molecules d'acides nucleiques stamp2, polypeptides, et procedes diagnostiques et therapeutiques
GB2379660A (en) * 2001-01-30 2003-03-19 Aeomica Inc Human GTP-Rho binding protein 2
EP1231216A3 (fr) * 2001-01-30 2004-03-17 Aeomica, Inc. Protéine humaine qui se lie au gtp-rho
CA2459318C (fr) 2001-09-06 2017-09-26 Agensys, Inc. Acide nucleique et proteine correspondante designes par steap-1 utiles dans le traitement et la detection du cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JP2005534287A (ja) * 2002-04-05 2005-11-17 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な９８ｐ４ｂ６との名称の核酸および対応するタンパク質
JP5840351B2 (ja) * 2002-09-06 2016-01-06 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な９８ｐ４ｂ６と称される、核酸および対応タンパク質
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
GB0326834D0 (en) * 2003-11-18 2003-12-24 Celltech R&D Ltd A protein involved in lung cancer
TWI238677B (en) 2003-12-25 2005-08-21 Fujitsu Ltd Organic EL element, organic EL display, process for fabricating organic EL element, and device for fabricating organic EL element
DK1742966T3 (da) 2004-04-22 2014-02-03 Agensys Inc Antistoffer og molekyler afledt deraf som binder til STEAP-1 proteiner
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
CA2667019C (fr) 2006-10-27 2016-03-29 Genentech, Inc. Anticorps et immunoconjugues, et leurs utilisations
US8426673B2 (en) * 2008-01-11 2013-04-23 Astellas Pharma, Inc. Pathological animal model for pelvic pain syndrome
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
WO2011156328A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugués modifiés par la cystéine
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
SG11201401406YA (en) 2011-10-14 2014-05-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
PT2906298T (pt) 2012-10-12 2018-12-28 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpos
SMT201800346T1 (it) 2012-10-12 2018-09-13 Medimmune Ltd Coniugati pirrolobenzodiazepina-anticorpo
WO2014057122A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps anti-cd22 - pyrrolobenzodiazépine
WO2014057074A1 (fr) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
EP2906250B1 (fr) 2012-10-12 2018-05-30 ADC Therapeutics SA Conjugués pyrrolobenzodiazepine-anticorps anti-psma
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
JP6307519B2 (ja) 2012-12-21 2018-04-04 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンおよびその結合体
CN110627797A (zh) 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
EP2968596B1 (fr) 2013-03-13 2019-03-06 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP6752204B2 (ja) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド 四級アミン化合物及びその抗体−薬物コンジュゲート
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
EP3464280B1 (fr) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
ES2871001T3 (es) 2017-02-08 2021-10-28 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
ES2955852T3 (es) 2017-04-03 2023-12-07 Hoffmann La Roche Anticuerpos de unión a STEAP-1
WO2018192944A1 (fr) 2017-04-18 2018-10-25 Medimmune Limited Conjugués de pyrrolobenzodiazépine
CA3057748A1 (fr) 2017-04-20 2018-10-25 Adc Therapeutics Sa Polytherapie avec un conjugue anticorps anti-axl-medicament
ES2988683T3 (es) 2017-06-14 2024-11-21 Adc Therapeutics Sa Pautas posológicas para la administración de un CAF anti-CD19
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20220156974A (ko) 2017-09-20 2022-11-28 주식회사 피에이치파마 타일란스타틴 유사체
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (fr) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Inducteurs chimiques conjugués de dégradation et méthodes d'utilisation
EP3894427A1 (fr) 2018-12-10 2021-10-20 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022078524A2 (fr) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
EP4637833A2 (fr) 2022-12-23 2025-10-29 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062941A2 (fr) * 1998-06-01 1999-12-09 Urogenesys, Inc. Nouveaux antigenes transmembranaires du type serpentin exprimes dans des cancers humains et utilisation de ces antigenes
WO2000073509A2 (fr) * 1999-06-01 2000-12-07 Incyte Genomics, Inc. Molecules utilisees a des fins diagnostiques et therapeutiques
WO2001005970A2 (fr) * 1999-07-19 2001-01-25 Incyte Genomics, Inc. Proteines associees de liaison gtp

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5820880A (en) * 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
US6048970A (en) * 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062941A2 (fr) * 1998-06-01 1999-12-09 Urogenesys, Inc. Nouveaux antigenes transmembranaires du type serpentin exprimes dans des cancers humains et utilisation de ces antigenes
WO2000073509A2 (fr) * 1999-06-01 2000-12-07 Incyte Genomics, Inc. Molecules utilisees a des fins diagnostiques et therapeutiques
WO2001005970A2 (fr) * 1999-07-19 2001-01-25 Incyte Genomics, Inc. Proteines associees de liaison gtp

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI; 10 December 1999 (1999-12-10), EMMANUEL DIAS NETO ET AL: "SHOTGUN SEQUENCING OF THE HUMAN TRANSCRIPTOME WITH ORF EXPRESSED SEQUENCE TAGS", XP002279053, Database accession no. AI908168 *
DATABASE EMBL [online] EBI; 22 February 2000 (2000-02-22), ISOGAI T., OTSUKI T., XP002241852, Database accession no. AK001691 *
DATABASE EMBL [online] EBI; 26 April 1999 (1999-04-26), MAHAIRAS G.G ET AL.: "Sequence-tagged connectors...", Database accession no. AQ456610 *
DIATCHENKO L ET AL: "SUPPRESSION SUBTRACTIVE HYBRIDIZATION: A METHOD FOR GENERATING DIFFERENTIALLY REGULATED OR TISSUE-SPECIFIC CDNA PROBES AND LIBRARIES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, 1 June 1996 (1996-06-01), pages 6025 - 6030, XP002911922, ISSN: 0027-8424 *
MAHAIRAS G G ET AL: "SEQUENCE-TAGGED CONNECTORS: A SEQUENCE APPROACH TO MAPPING AND SCANNING THE HUMAN GENOME", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 17, AQ456610, August 1999 (1999-08-01), pages 9739 - 9744, XP002175436, ISSN: 0027-8424 *
WATANABE G ET AL: "PROTEIN KINASE N (PKN) AND PKN-RELATED PROTEIN RHOPHILIN AS TARGETS OF SMALL GTPASE RHO", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 271, no. 5249, 2 February 1996 (1996-02-02), pages 645 - 648, XP001109460, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
AU4941101A (en) 2001-10-08
CA2403637A1 (fr) 2001-10-04
AU2001249411B2 (en) 2007-02-15
WO2001072962A2 (fr) 2001-10-04
JP2004521602A (ja) 2004-07-22
EP1268526A2 (fr) 2003-01-02
AU2001249411B9 (en) 2001-10-08
WO2001072962A3 (fr) 2002-01-17

Similar Documents

Publication Publication Date Title
AU4941101A (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
AU3510200A (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
EP1379631A4 (fr) Proteines kinases humaines isolees, molecules d'acides nucleiques codant ces proteines kinases, et utlisations correspondantes
EP1414847A4 (fr) Proteines isolees secretees par l'humain, molecules d'acides nucleiques codant pour ces proteines secretees par l'humain et leur utilisation
EP1414844A4 (fr) Proteines humaines secretees et isolees, molecules d'acide nucleique codant les proteines humaines secretees et utilisation de ces dernieres
EP1425289A4 (fr) Nouvelles molecules d'acide nucleique et polypeptidiques
AU2001250999A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002213450A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
AU2002239256A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
EP1379629A4 (fr) Proteines humaines isolees metabolisant le medicament, molecules d'acides nucleiques codant pour ces proteines et utilisations associees
EP1383907A4 (fr) Proteines proteasiques humaines isolees, molecules d'acides nucleiques codant pour ces proteines proteasiques humaines et utilisations associees
EP1383871A4 (fr) Proteines enzymatiques humaines isolees, molecules d'acides nucleiques codant pour ces proteines, et leurs utilisations
AU2001271276A1 (en) Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof
EP1385991A4 (fr) Proteines enzymatiques humaines isolees, molecules d'acide nucleique codant lesdites proteines et utilisations associees
EP1383908A4 (fr) Proteines enzymatiques humaines isolees, molecules d'acides nucleiques codant des proteines enzymatiques humaines et utilisations de celles-ci
EP1383877A4 (fr) Proteines enzymatiques humaines isolees, molecules d'acides nucleiques codant des proteines enzymatiques humaines, et utilisations associees
EP1414422A4 (fr) Proteines humaines isolees secretees, molecules d'acides nucleiques codant pour lesdites proteines et utilisations de ces proteines
EP1414863A4 (fr) Proteines secretees humaines isolees, molecules d'acide nucleique codantes pour ces proteines secretees humaines et utilisations de celles-ci
EP1395674A4 (fr) Proteines proteases humaines isolees, molecules d'acide nucleique codant des proteines proteases humaines et leurs utilisations
EP1379678A4 (fr) Proteines isolees humaines de la protease, molecules d'acide nucleique codant les proteines humaines de la protease et leurs utilisations
EP1383876A4 (fr) Proteines enzymatiques humaines isolees, molecules d'acides nucleiques codant des proteines enzymatiques humaines et leurs utilisations
EP1390486A4 (fr) Aminoacylase humaine isolee, molecules d'acide nucleique codant l'aminoacylase humaine, et leurs utilisations
EP1373294A4 (fr) Proteines d'enzymes humaines isolees, molecules d'acide nucleique codant des proteines d'enzymes humaines, et leurs utilisations
AU2002234023A1 (en) Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
EP1383873A4 (fr) Proteines kinase humaines isolees, molecules d'acide nucleique codant les proteines kinase humaines et utilisation correspondante

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021023

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/00 B

Ipc: 7C 07K 14/72 B

Ipc: 7G 01N 33/53 A

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE FR GB LI

A4 Supplementary search report drawn up and despatched

Effective date: 20040727

17Q First examination report despatched

Effective date: 20070503

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071114